GLP-1 tablets: can you now lose weight without injections?

Information verified on 6 September 2026. The US approvals cited do not prejudge the status in Morocco. This information sheet is not a substitute for medical advice.

Yes, GLP-1-based treatments are available in oral form. However, ‘without injections’ does not mean either without a prescription or without side effects. To understand this development, three questions must be considered separately: which medicine was studied, for which indication was it authorised, and in which country can it be prescribed?

What has changed with orforglipron

On 1 April 2026, the US FDA authorised Foundayo, whose active ingredient is orforglipron, for weight loss and weight maintenance in certain adults: those living with obesity, or those who are overweight and have at least one weight-related complication. The authorisation requires dietary support and physical activity. It is taken orally once daily, without the need to take it on an empty stomach. These details apply to the United States. Source: FDA decision.

This new development may make treatment more acceptable for someone who is afraid of injections. It does not allow you to choose your own medication: medical history, other treatments, digestive tolerance and the possibility of follow-up care remain key factors.

A tablet and an injection cannot be compared solely on the basis of their form

How to interpret the results without being put off by a percentage

The ATTAIN-1 trial compared orforglipron with a placebo over 72 weeks in adults with obesity. The treatment was given in addition to dietary and exercise measures. The average weight loss was greater with orforglipron, but an average result does not predict an individual’s outcome. Dropouts and adverse effects are just as important as the final figure. Source: published results of the ATTAIN-1 trial.

Two figures from two different trials are not sufficient to classify medicines. Participants who are diabetic or non-diabetic, a longer follow-up period, a different analytical method or a different treatment regimen may alter the result. A direct comparison, where available, provides a better answer to this question.

The precautions are the same as for a genuine treatment

The FDA specifically highlights gastrointestinal effects and precautions regarding pancreatitis, dehydration, the gallbladder and certain interactions. Its package leaflet also includes a contraindication in cases of a personal or family history of medullary thyroid cancer or MEN 2 syndrome. Orforglipron must not be used in combination with another GLP-1 agonist. The prescriber should assess these points; this page does not provide a dosing regimen.

In Morocco, the right questions to ask

An American advert does not prove that a product is authorised, available or reimbursed in Morocco. Before taking any action, ask a doctor and a pharmacist to check the exact status of the product and its supply chain.

• Does my medical condition correspond to a recognised indication?
• What nutritional and medical monitoring is provided?
• Which side effects should prompt you to seek medical advice?
• How should I manage my other medicines and my plans to conceive?
• What is the long-term plan, including if treatment is stopped?

To prepare for this discussion, please also read our feature on discontinuing a GLP-1 and organising meals when your appetite wanes.

Original illustration generated by AI; it does not represent an identified commercial product or a real clinical situation.